Rangering i aksjer
#33757
Lucira Health, Inc. is a medical technology enterprise dedicated to the... Lucira Health, Inc. is a medical technology enterprise dedicated to the development and commercialization of diagnostic test kits for infectious diseases. The company has innovated a platform capable of providing molecular testing capabilities. Among its current product offerings is the LUCIRA COVID-19 All-In-One Test Kit, and it is also progressing with the development of diagnostic solutions for influenza A and B viruses. Lucira Health holds a patent license agreement with Eiken Chemical Co., Ltd., alongside technical and manufacturing service agreements with Jabil, Inc. and Jabil MSA, respectively. Founded in 2013, the company operated as DiAssess Inc. until January 2020 when it rebranded to Lucira Health, Inc. Its main offices are situated in Emeryville, California.
Aksjekurs
$0.4523
Sist synkronisert: 2023-03-03
Handel Lucira Health, Inc. (LHDX)
Pris LHDX pris med markedsverdi på B
Markedsverdi av Lucira Health, Inc.(LHDX)
Markedsverdi: $6.97M
Per August 2026 har Lucira Health, Inc. en markedsverdi på $6.97M. Dette gjør Lucira Health, Inc. til det 33757th mest verdifulle selskapet i verden basert på markedsverdi ifølge våre data. Markedsverdi er den totale markedsverdien av et børsnotert selskaps utestående aksjer og brukes vanligvis til å måle hvor mye et selskap er verdt.
Markedsverdihistorikk for Lucira Health, Inc. fra 2021 til 2026
LHDX sammenlignet med topp 5 mest populære stocks
| Pris på LHDX |
|
Eiendel B |
Markedsverdi for B |
Resultater |
|
|
|
|
$5.452T
|
+78,259,697.47%
|
|
|
|
|
$4.490T
|
+64,452,686.87%
|
|
|
|
|
$4.162T
|
+59,749,906.09%
|
|
|
|
|
$3.676T
|
+52,772,606.31%
|
|
|
|
|
$2.833T
|
+40,667,310.32%
|
